Compare · EPRX vs NVCN
EPRX vs NVCN
Side-by-side comparison of Eupraxia Pharmaceuticals Inc. (EPRX) and Neovasc Inc. (NVCN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EPRX and NVCN operate in Pharmaceuticals and Biotechnology (Health Care), so they compete in similar markets.
- EPRX is the larger of the two at $440.4M, about 15.8x NVCN ($27.8M).
- EPRX has hit the wire 7 times in the past 4 weeks while NVCN has been quiet.
- EPRX has more recent analyst coverage (6 ratings vs 0 for NVCN).
- Company
- Eupraxia Pharmaceuticals Inc.
- Neovasc Inc.
- Price
- $7.17-1.51%
- $30.03+1.35%
- Market cap
- $440.4M
- $27.8M
- 1M return
- +1.13%
- -
- 1Y return
- +83.61%
- -
- Industry
- Pharmaceuticals and Biotechnology
- Pharmaceuticals and Biotechnology
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 7
- 0
- Recent ratings
- 6
- 0
NVCN
Neovasc Inc.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, Canada, the United States, and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Latest EPRX
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Eupraxia Pharmaceuticals
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Latest NVCN
- Volato Announces Changes to Board Composition
- SEC Form EFFECT filed by Neovasc Inc.
- SEC Form 15F-12B filed by Neovasc Inc.
- SEC Form 6-K filed by Neovasc Inc.
- SEC Form 6-K filed by Neovasc Inc.
- SEC Form RW filed by Neovasc Inc.
- SEC Form F-10POS filed by Neovasc Inc.
- SEC Form POS AM filed by Neovasc Inc.
- SEC Form S-8 POS filed by Neovasc Inc.
- SEC Form 25-NSE filed by Neovasc Inc.